RxDoctor Payments Data

Brian Dearing, MD

Interventional Cardiology · Fairhope, ALNPI 1164478178

Payments from drug & device makers

$964in general payments, 2019–2025

Across 24 payments — averaging $40.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$303
  • Boston Scientific$230
  • AstraZeneca$125
  • Philips North America LLC$107
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$48
  • Penumbra, Inc.$33
  • plus $118 from 7 others

What the payments were for

  • Food & beverage$964100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$964 in reported general payments places this provider in the 10th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$345,645
Medicare patients
1,613
Services billed
3,663

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban585$580,870
Repatha SureclickEvolocumab282$215,226
EntrestoSacubitril/Valsartan180$160,238
XareltoRivaroxaban145$151,372
MultaqDronedarone Hcl49$72,040
Praluent PenAlirocumab50$36,610
JardianceEmpagliflozin29$36,013
FarxigaDapagliflozin Propanediol40$28,966
Ranolazine ErRanolazine114$13,078
Atorvastatin Calcium875$11,178
Repatha PushtronexEvolocumab14$10,480
BrilintaTicagrelor15$7,519
Metoprolol Succinate449$5,712
Prasugrel Hcl87$5,205
Ezetimibe207$4,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$580,870585 claims
Johnson & JohnsonXarelto$15$151,372145 claims
AstraZenecaFarxiga, Brilinta$125$36,48555 claims
Boehringer IngelheimJardiance$15$36,01329 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Fairhope

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →